Skip to main content
. 2022 Feb;13(1):426–437. doi: 10.21037/jgo-21-274

Figure 1.

Figure 1

Schematic model of tumorigenic signaling pathways and their inhibition by anti-cancer-TKI. The figure is reused from the article below Eckstein N, Röper L, Haas B, et al. Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective. J Exp Clin Cancer Res 2014;33:15.